Anti-ischemic effects of nimesulide, a cyclooxygenase-2 inhibitor on the ischemic model of rabbit induced by isoproterenol

Archives of Pharmacal Research

Volumn 29, Issue 11, 2006, Pages 977-983

  Saeed, Sheikh Arshad ^a   Ahmed, Sagheer ^a  

^a UNIVERSITY OF KARACHI   (Pakistan)

Author keywords

Coronary perfusion rates (CPR); Creatine phosphokinase (CPK); Electrocardiography (ECG); Histopathology; Isoprenaline (ISP); Troponin I (TPI)

Indexed keywords

EID: 33845365244     PISSN: 02536269     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02969281     Document Type: Article

References (22)

1. Adams, J. E. 3rd., Bodor, G. S., Davila-Roman, V.G., Delmez, J. A., Apple, F. S., Ladenson, J. H., and Jaffe, A. S., Cardiac troponin I: a marker with high specificity for cardiac injury. Circulation, 88, 101-106 (1993).
2. Baker, C. S., Hall, R. J., Evans, T. J., Pomerance, A., Maclouf, J., Creminon, C., Yacoub, M. H., and Polak, J.M., Cyclooxygenase-2 is widely expressed in atherosclerotic lesions affecting native and transplanted human coronary arteries and colocalized with inducible nitric oxide synthase and nitrotyrosine particularly in macrophages. Arterioscler. Thromb. Vasc. Biol., 19, 646-655 (1999).
3. Belton, O., Byrne, D., Kearney, D., Leahy, A., and Fitzgerald, D. J., Cyclooxygenase-1 and -2 dependent prostacyclin formation in patients with atherosclerosis. Circulation, 102, 840-845 (2000).
4. Bombardier, C., Laine, L., Reicin, A., Shapiro, D., Burgos-Vargas, R., Davis, B., Day, R., Ferraz, M. B., Hawkey, C. J., Hochberg, M. C., Kvien, T. K., and Schnitzer, T. J., Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis: VIGOR Study Group. N. Engl. J. Med., 243, 1520-1528 (2000).
5. Bonow, R. O., Lipson, L. C., Shaheen, F. H., Capurro, N. L., Inser, J. M., Roberst, W.C., Goldstein, R. E., and Epstein, S.E., Lack of effect of aspirin on myocardial infarct size in dogs. Am. J. Cardiol., 47, 258-264 (1981).
6. Cai, H. and Harrison, D. G., Endothelial dysfunction in cardiovascular disease: the role of oxidant stress. Cirs. Res., 87, 840-844 (2000).
7. Chenevard, R., Hurlimann, D., Bechir, M., Enseleit, F., Spieker, L., Hermann, M., Riesen, W., Gay, S., Gay, R. E., Neidhart, M., Michel, B., Luscher, T. F., Noll, G., and Ruschitzka, F., Selective COX-2 inhibition improves endothelial function in coronary artery disease. Circulation, 107, 405-409 (2003).
8. Duffy, S. J., Castle, S. F., Harper, R. W. et al., Contribution of vasodilator prostanoids and nitric oxide to resting flow, metabolic vasodilatation, and flow-mediated dilation in human coronary circulation. Circulation, 100, 1951-1957 (1999).
9. Heitzer, T., Just, H., and Munzel, T., Antioxidant vitamin C improves and endothelial dysfunction in chronic smokers. Circulation, 94, 6-9 (1996).
10. Koenig, W., Inflammation and coronary heart disease: an overview. Caridol. Rev., 9, 31-35 (2001).
11. Langendorff. Pfluners Arch. Ges. Physiol., 190, 280 (1985).
12. Lecomte, M., Laneuville, O., Ji, C., DeWitt, D. L., and Smith, W. L., Acetylation of human prostaglandin endoperoxide synthase-2 (cyclooxygenase-2) by aspirin. J. Biol. Chem., 269, 13207-13215 (1994).
13. Mobert, J. and Becker, B. F., Cyclooxygenase inhibition aggravates ischaemia-reperfusion injury in the perfused guinea pig heart: involvement of isoprostanes. J. Am. Coll. Cardiol., 31, 1687-1694 (1998).
14. Mukerjee, D., Nissen, S. E., and Topol, E. J., Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA. 286, 954-959 (2001).
15. Mukerjee, D., Selective Cyclooxygenase-2 (COX-2) inhibitors and potential risk of cardiovascular events. Biochem. Pharmacol., 63, 817-21 (2002).
16. O'Banion M., Cyclooxygenase-2: Molecular biology, pharmacology and neurobiology. Critc. Rev. Neurobiol., 13, 45-82 (1999).
17. Rosalki, S. B., An improved procedure for serum creatine phosphokinase determination. J. Lab. Clin. Med., 69, 696-705 (1967).
18. Saeed, S. A., Atiq, M., Virani, S., and Gilani, A. H., New vistas in the therapeutic uses of aspirin. Res. Commun. Pharmacol. Toxicol., 6, 277-296 (2001).
19. Saeed, S. A., Gilani, A. H., Sultan, B. H., Karim, R. M., and Shah, B. H., Myocardial ischemia and infarction in isoprenaline-treated rabbits: Role of cyclooxygenases. Bichem. Soc. Trans., 26, S342 (1998).
20. Saito, T., Rodger, I. W., Hu, F., Shennib, H., and Giaid, A., Inhibition of cyclooxygenase-2 improves cardiac function in myocardial infarction. Biochem. Biphys. Res. Commun., 273, 772-775 (2000).
21. Schonbeck, U., Sukhova, G. K., Graber, P., Coulter, S., and Libby, P., Augmented expressoin of cyclooxygenase-2 in human atherosclerotic lesions. Am. J. Pathol., 155, 1281-1291 (1999).
22. Silverstein, F. E., Faich, G., Goldstein, J. L., Simon, L. S., Pincus, T., Whelton, A., Makuch, R., Eisen, G., Agrawal, N. M., Stenson, W. F., Burr, A. M., Zhao, W. W., Kent, J. D., Lefkowith, J. B., Verburg, K. M., and Geis, G. S., Gastrointestinal toxicity with celecoxib vs nonsterodial anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS Study. A randomized control trial. JAMA, 284, 1247-1255 (2000).